Literature DB >> 15917471

Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.

Daniel J Pearce1, David Taussig, Catherine Simpson, Kirsty Allen, Ama Z Rohatiner, T Andrew Lister, Dominique Bonnet.   

Abstract

Aldehyde dehydrogenase (ALDH) is a cytosolic enzyme that is responsible for the oxidation of intracellular aldehydes. Elevated levels of ALDH have been demonstrated in murine and human progenitor cells compared with other hematopoietic cells, and this is thought to be important in chemoresistance. A method for the assessment of ALDH activity in viable cells recently has been developed and made commercially available in a kit format. In this study, we confirmed the use of the ALDH substrate kit to identify cord blood stem/progenitor cells. Via multicolor flow cytometry of cord blood ALDH+ cells, we have expanded on their phenotypic analysis. We then assessed the incidence, morphology, phenotype, and nonobese diabetic/ severe combined immunodeficiency engraftment ability of ALDH+ cells from acute myeloid leukemia (AML) samples. AML samples had no ALDH+ cells at all, an extremely rare nonmalignant stem/progenitor cell population, or a less rare, leukemic stem cell population. Hence, in addition to identifying nonmalignant stem cells within some AML samples, a high ALDH activity also identifies some patients' CD34+/ CD38- leukemic stem cells. The incidence of normal or leukemic stem cells with an extremely high ALDH activity may have important implications for resistance to chemotherapy. Identification and isolation of leukemic cells on the basis of ALDH activity provides a tool for their isolation and further analysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917471     DOI: 10.1634/stemcells.2004-0292

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  102 in total

1.  The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance.

Authors:  Jan S Moreb; Deniz Ucar; Shuhong Han; John K Amory; Alex S Goldstein; Blanca Ostmark; Lung-Ji Chang
Journal:  Chem Biol Interact       Date:  2011-11-03       Impact factor: 5.192

2.  Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas.

Authors:  Benito Campos; Franz-Simon Centner; Justo Lorenzo Bermejo; Ramadan Ali; Katharina Dorsch; Feng Wan; Jörg Felsberg; Rezvan Ahmadi; Niels Grabe; Guido Reifenberger; Andreas Unterberg; Jürgen Burhenne; Christel Herold-Mende
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

3.  Chemoradiation therapy reduces aldehyde dehydrogenase 1 expression in cervical cancer but does not improve patient survival.

Authors:  Yin Lv; Lin Yang; Fan Wang
Journal:  Med Oncol       Date:  2015-04-03       Impact factor: 3.064

4.  Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.

Authors:  Ines A Silva; Shoumei Bai; Karen McLean; Kun Yang; Kent Griffith; Dafydd Thomas; Christophe Ginestier; Carolyn Johnston; Angela Kueck; R Kevin Reynolds; Max S Wicha; Ronald J Buckanovich
Journal:  Cancer Res       Date:  2011-04-15       Impact factor: 12.701

5.  Stem cells, phenotypic inversion, and differentiation.

Authors:  Robert W Siggins; Ping Zhang; David Welsh; Nicole J Lecapitaine; Steve Nelson
Journal:  Int J Clin Exp Med       Date:  2008-01-20

6.  Aldehyde dehydrogenase activity enriches for proximal airway basal stem cells and promotes their proliferation.

Authors:  Ahmed E Hegab; Vi Luan Ha; Bharti Bisht; Daphne O Darmawan; Aik T Ooi; Kelvin Xi Zhang; Manash K Paul; Yeon Sun Kim; Jennifer L Gilbert; Yasser S Attiga; Jackelyn A Alva-Ornelas; Derek W Nickerson; Brigitte N Gomperts
Journal:  Stem Cells Dev       Date:  2014-01-02       Impact factor: 3.272

7.  Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.

Authors:  Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Antonio Segura-Carretero; Jorge Joven; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Cell Cycle       Date:  2013-09-17       Impact factor: 4.534

Review 8.  Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity.

Authors:  Breann Yanagisawa; Gabriel Ghiaur; B Douglas Smith; Richard J Jones
Journal:  Exp Hematol       Date:  2016-09-28       Impact factor: 3.084

Review 9.  In search of liver cancer stem cells.

Authors:  Stephanie Ma; Kwok Wah Chan; Xin-Yuan Guan
Journal:  Stem Cell Rev       Date:  2008-07-29       Impact factor: 5.739

Review 10.  Clinical implications of cancer stem cell biology in hepatocellular carcinoma.

Authors:  Junfang Ji; Xin Wei Wang
Journal:  Semin Oncol       Date:  2012-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.